In yesterday’s Wall Street session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares traded at $4.57, down -6.16% from the previous session.
13 analysts cover Iovance Biotherapeutics Inc (NASDAQ:IOVA), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $38.00 and a low of $14.00, we find $20.00. Given the previous closing price of $4.87, this indicates a potential upside of 310.68 percent. IOVA stock price is now -30.38% away from the 50-day moving average and -33.61% away from the 200-day moving average. The market capitalization of the company currently stands at $1.13B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 10. Brokers who have rated the stock have averaged $22.36 as their price target over the next twelve months.
With the price target reduced from $40 to $18, Barclays maintained Overweight rating for Iovance Biotherapeutics Inc (NASDAQ: IOVA).
In other news, MCPEAK MERRILL A, Director bought 10,000 shares of the company’s stock on Sep 18. The stock was bought for $55,600 at an average price of $5.56. Upon completion of the transaction, the Director now directly owns 248,633 shares in the company, valued at $1.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 15, Director Rothbaum Wayne P. bought 5,000,000 shares of the business’s stock. A total of $26,500,000 was incurred on buying the stock at an average price of $5.30. This leaves the insider owning 23,067,333 shares of the company worth $105.42 million. A total of 19.33% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IOVA stock. A new stake in Iovance Biotherapeutics Inc shares was purchased by HOOD RIVER CAPITAL MANAGEMENT LLC during the first quarter worth $9,028,000. EXODUSPOINT CAPITAL MANAGEMENT, LP invested $2,056,000 in shares of IOVA during the first quarter. In the first quarter, POLAR ASSET MANAGEMENT PARTNERS INC. acquired a new stake in Iovance Biotherapeutics Inc valued at approximately $1,813,000. SG AMERICAS SECURITIES, LLC acquired a new stake in IOVA for approximately $1,679,000. STATE OF NEW JERSEY COMMON PENSION FUND D purchased a new stake in IOVA valued at around $1,253,000 in the second quarter. In total, there are 334 active investors with 73.97% ownership of the company’s stock.
On Monday morning Iovance Biotherapeutics Inc (NASDAQ: IOVA) stock kicked off with the opening price of $4.8300. During the past 12 months, Iovance Biotherapeutics Inc has had a low of $4.41 and a high of $10.41. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 3.10, and a quick ratio of 2.99. The fifty day moving average price for IOVA is $6.5004 and a two-hundred day moving average price translates $6.8680 for the stock.
The latest earnings results from Iovance Biotherapeutics Inc (NASDAQ: IOVA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.47, beating analysts’ expectations of -$0.8 by 0.33. This compares to -$0.63 EPS in the same period last year. The net profit margin was -175981.09% and return on equity was -79.68% for IOVA. For the current quarter, analysts expect IOVA to generate $4.19M in revenue.
